Viking Therapeutics positions itself as an innovative player in the biopharmaceutical sector, specializing in the development of targeted treatments for metabolic and endocrine diseases, a segment with significant unmet medical needs that remains underexploited. Its model is based on advancing differentiated clinical programs, allowing it to occupy a high-value niche. The company relies on its ability to turn its research into drug candidates with strong commercial potential.